Edgar Filing: IMMUNOGEN INC - Form 4

IN ALTNICOTINE IN

Form 4	EN INC										
January 11, 2	2016										
FORM 4 LINITED STATES SECURITIES AND EXCHANCE O								OMB APPROVAL			
	UNITED	Washington, D.C. 20549							OMB Number:	3235-0287	
Check th if no long subject to Section 1 Form 4 o	ger STATEN 6. r	STATEMENT OF CHAN							Expires: January 31 2009 Estimated average burden hours per response 0.5		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities E Section 17(a) of the Public Utility Holding Compan 30(h) of the Investment Company Ac								1935 or Section	1		
(Print or Type I	Responses)										
Gregory Richard J. Symbol			Symbol	ol				5. Relationship of Reporting Person(s) to Issuer			
Ι				IMMUNOGEN INC [IMGN]				(Check all applicable)			
				of Earliest Transaction /Day/Year) 2016				Director 10% Owner X Officer (give title Other (specify below) Executive VP & CSO			
			Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
WALTHAN	A, MA 02451							Form filed by M Person	ore than One Rej	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-E	Derivative	Secur	ities Acqu	iired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deem Execution any (Month/Da	Date, if	3. 4. Securities Acquired Transactior(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V	Amount	or (D)	Price	Transaction(s) (Instr. 3 and 4)			
Common Stock	01/08/2016			S	2,369 (2)	D	\$ 11.104 (1)	22,631	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: IMMUNOGEN INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	unt of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Gregory Richard J. C/O IMMUNOGEN, INC. 830 WINTER STREET WALTHAM, MA 02451			Executive VP & CSO					
Signatures								
/s/ Craig Barrows, attorney in fact	()1/11/2016						
**Signature of Reporting Person		Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Weighted average price of shares sold.

The transaction reported in this Form 4 was made in connection with the satisfaction of the reporting person's tax withholding obligation(2) arising from the vesting of restricted shares and was effected pursuant to a 10b5-1 trading plan executed by the reporting person on December 11, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.